Free Newsletter
Scripps Florida unveils $600M research facility
Scripps Florida officially opened its doors last week as a host of regional politicians descended on Jupiter, FL to herald a project intended to push the Sunshine state into the front ranks of biomedical research. The 350,000 square foot facility was built with $310 million approved by the state legislature and $187 million provided by Palm Beach County--on top of $100 million the county invested in the original site. And Scripps Florida researchers have been at work in temp space working on a slate of diseases including Alzheimer's, Parkinson's, autism, as well as HIV/AIDS and tuberculosis.
Richard Lerner, president of The Scripps Research Institute, told lawmakers last week that the area could be an early beneficiary of billions of dollars in new federal research money provided in the new stimulus package.
"Much of the country now is looking to build what we have now out of the stimulus package," Lerner said. "The question now is how do we take advantage of all that? How do we leverage what we have to go forward?"
"What we can promise is that many important things will happen in those buildings," Lerner told the crowd during the opening ceremony. "We just don't know what," he said. "It's the unpredictability of science that makes it so exciting and so interesting."
- check out the report from the Palm Beach Post
- and read the story from the Sun-Sentinel
Related Articles:
Scripps to study how people react to genetic data
Scripps to build HIV research center
Scripps Florida sees first biotech spinoff take root
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: